Kotz, Deborah2020-06-012020-06-012020-05-28http://hdl.handle.net/10713/12894News release announcing that researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe. Additional information available via the accompanying video.en-USCoronavirus Disease 2019 (COVID-19)Mesoblast Limitedremestemcel-LUniversity of Maryland, BaltimoreUniversity of Maryland Medical CenterCOVID-19 (Disease)Stem Cell ResearchCOVID-19Article